Pressemitteilung -

Now Live: SolyPlus GmbH | Disruptive technology for innovative use of biopolymers

Hello,

we are pleased to again enable you to invest in SolyPlus GmbH today. The disruptive SolyPlus technology takes naturally occurring biopolymers that cannot otherwise be industrially processed and transforms them into a new form ("Smart Materials"), enabling highly innovative cosmetic and medical device products. SolyPlus products are sustainable, environmentally friendly and reduce medical shortages.

SolyPlus has already launched five products in the cosmetics and food sectors. These include anti-viral and anti-bacterial chitosan-containing chewing gums and candies, as well as peelings with high-dosage hyaluronic acid (up to 10%) - a world first. SolyPlus markets its cosmetic products under its own SolyPure Cosmetics brand. For other products, SolyPlus grants licenses, which enables rapid scaling with manageable fixed costs.

In the future, the focus will be on medical applications. For example, self-dissolving wound dressings and orthopedic material as well as microneedles for pain-free injections made of pure hyaluronic acid. With the prototypes already in place, SolyPlus is in negotiations with several German specialist companies who are very interested in taking over further development and marketing.

SolyPlus has already been able to convince several business angels, who have invested a total of €270,000. The funding threshold has thus already been exceeded. In the last financing round SolyPlus reached 500.000€ in 30 days. Take the chance now to participate in the success of SolyPlus at Early-Bird conditions.

Top reasons to invest in SolyPlus

The perfect time for an investment

  • Investors are enthusiastic about SolyPlus: already more than 270,000€ invested, in the last financing round SolyPlus reached 500,000€ in 30 days
  • Five innovative products based on SolyPlus technology launched in 2020 to 2022
  • Four license partners already signed up to use the disruptive technology

High problem-solving potential of SolyPlus technology
  • Prevention solution for viral or bacterial infections (chitosan products)
  • Improvement of modern medical care, e.g. in the field of wound care and wound management
  • Sustainable SolyPure Cosmetics products replace products containing microplastics
Only for a short time: For all investors who invest up to and including 14.08., a company valuation of € 5.125 million instead of € 5.75 million applies. Take the chance now and invest in SolyPlus at discounted conditions.

Links

Themen

  • Medizin, Pharmazeutik

SolyPlus GmbH 2022 | Disruptive technology for the innovative use of biopolymers

We transform naturally occurring biopolymers into a new format ("smart materials") so that their full potential can be harnessed for highly innovative medical devices and cosmetic applications. Our products are not only sustainable and environmentally friendly, but also help to overcome unmet medical needs. In the meantime, we have already launched five products in the cosmetics and food sectors.

Kontakt

Zugehörige Meldungen

  • Ho Ho Ho! Frohe Weihnachten!

    Ho Ho Ho! Frohe Weihnachten! Wir wünschen euch von Herzen zauberhafte und erholsame Feiertage, erfüllt mit Glück und Zufriedenheit und mit viel Zeit für Gemütlichkeit. ✨⁠
    ⁠Hat es bei euch dieses Jahr mit der weißen Weihnacht geklappt? Bei uns im Norden ist der Schnee leider schon wieder verschwunden! Aber auch ohne Schnee klappt es bei uns mit der Weihnachtsstimmung 😊⁠
    ⁠Hoffentlich habt ihr

  • FGK Clinical Research GmbH aus München trifft SolyPlus GmbH aus Nordfriesland als erster strategischer Investor in der zweiten Finanzierungsrunde

    Die SolyPlus GmbH ist eine Start-up-Biotechnologiefirma, die seit 2020 in Haselund bei Husum, Nordfriesland, aus natürlich vorkommenden Biopolymeren wie Hyaluronsäure, Chitosan und anderen, innovative Produkte für die Kosmetik und den Medizintechnikbereich entwickelt. Die Grundlage dieser Produkte ist die von der Bundesagentur für Sprunginnovationen SPRIND identifizierte Technologie-Plattform, die

  • Update zur SprinD-Evaluierung

    Im September 2022 wurde SolyPlus von SPRIND mit der Validierung der SolyPlus-Technologie anhand entsprechender Untersuchungen an den Wundauflagen, Mikronadeln und Implantaten beauftragt. Diese Validierung ist auf dem besten Wege, ein voller Erfolg zu werden.
    •Erste rheologische Untersuchungen haben gezeigt, welchen Einfluss Wassergehalt, Molekulargewicht und Chargenmischungen auf die optimale